Christopher Sansone - 17 May 2022 Form 4 Insider Report for InfuSystem Holdings, Inc (INFU)

Role
Director
Signature
/s/ Kevin Whitman, Attorney-in-Fact for Christopher R. Sansone
Issuer symbol
INFU
Transactions as of
17 May 2022
Net transactions value
$0
Form type
4
Filing time
17 May 2022, 17:00:50 UTC
Previous filing
22 Feb 2022
Next filing
21 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding INFU Common Stock 25,000 17 May 2022 Direct
holding INFU Common Stock 1,464,916 17 May 2022 See F1
holding INFU Common Stock 228,118 17 May 2022 See F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INFU Stock Option (right to buy) Award $0 +25,000 $0.000000 25,000 17 May 2022 Common Stock 25,000 $8.58 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported securities are directly owned by Sansone Partners, L.P., a Delaware limited partnership. The Reporting Person is the managing member of (i) the general partner of this limited partnership and (ii) the investment manager of this limited partnership and, as such, may be deemed to indirectly beneficially own the shares held by this limited partnership. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F2 The reported securities are directly owned by Sansone Partners (QP), L.P., a Delaware limited partnership. The Reporting Person is the managing member of (i) the general partner of this limited partnership and (ii) the investment manager of this limited partnership and, as such, may be deemed to indirectly beneficially own the shares held by this limited partnership. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F3 The stock option was issued with an exercise price equal to the Fair Value as defined by the 2021 Equity Plan, which is computed as the closing price of the Company's common stock reported on the NYSE American LLC on the date of grant.
F4 The option, representing the right to purchase 25,000 shares of InfuSystem Holdings, Inc. common stock, vests on the date of the 2023 annual shareholder meeting.